Ep 78 | Government Shutdown, Most Favored Nations Pricing and Direct-to-Consumer Pharmacy Supply Chain Discussion

In this week’s episode, Greg and Rob catch up on newsworthy developments in the 340B community. They’ll discuss various state and federal legislative developments, they’ll share how recent White House...

3 Helmi 202534min

In our first episode of 2025, Greg and Rob discuss the latest developments in 340B. They’ll recap HRSA audit trends, discuss how Congressional committee membership seems to be forming, and discuss a v...

15 Tammi 202548min

In our last episode of 2024, Greg and Rob recap major developments in the 340B space from the last year.  They’ll start with trends in HRSA audit activity, including thoughts on patient definition. Th...

17 Joulu 20241h 2min

In this week’s episode, Greg and Rob cover the recent policy notice put out by Sanofi regarding a 340B credit model. They discuss how it compares to other proposed credit/rebate models, and more impor...

2 Joulu 202451min

In this episode, Greg and Rob are joined by Rodney Whitlock, healthcare policy expert, to discuss the recent 2024 election results.    They’ll discuss what the second Trump Administration might priori...

14 Marras 202454min

In this episode, Greg and Rob are joined by Mike Strazzella, government affairs expert from Buchanan Ingersoll & Rooney, to discuss the upcoming general election, and what races may be critical to fut...

28 Loka 202455min

In this episode, Greg and Rob discuss the various uses of 340B billing modifiers. They’ll discuss some general considerations around what billing modifiers are used for, highlight differences between ...

14 Loka 202458min

In this episode, Greg and Rob get back to 340B basics and have a conversation around the concept of “clean site” 340B-only locations.  They discuss what “clean site” means in the world of 340B, what t...

1 Loka 202450min